Stockreport

CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human]) [Yahoo! Finance]

CSL LTD SP/ADR  (CSLLY) 
NASDAQ:AMEX Investor Relations: csl.com/investors
PDF Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human]) compared to placebo in reducing the risk of major adverse cardiovascular [Read more]